

Middle East and Africa Tumor Ablation Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Middle East and Africa Tumor Ablation Market Report and Forecast 2024-2032

Middle East and Africa Tumor Ablation Market Size

The global tumor ablation market was valued at USD 1.9 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising incidence of cancer. It is expected to grow at a CAGR of 11.70% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.

Middle East and Africa Tumor Ablation Market Outlook

- Recent data reveals that the number of new cancer cases in Saudi Arabia is estimated to reach 60,429 by 2040 . The rising incidence of cancer is expected to directly impact the market demand.
- The market share is influenced by the increased government initiatives aimed at improving cancer care and treatment access. For instance, in August 2023, a Memorandum of Understanding was signed in Abuja (Nigeria) to tackle the rising cancer burden and improve cancer care.
- One of the major Middle East and Africa tumor ablation market trends is the increasing introduction of advanced ablation techniques in healthcare facilities. In January 2023, Tawam Hospital in the United Arab Emirates announced that they performed a thyroid radiofrequency and microwave ablation procedure for the first time to treat a patient with a large compressive benign thyroid nodule.

Middle East and Africa Tumor Ablation Market Analysis

Tumor ablation is a technique that can destroy tumor cells with minimal damage to the surrounding tissues. The procedure involves inserting a needle or probe directly into the tumor, guided by the help of imaging techniques like ultrasound, CT, or MRI. It is increasingly utilized in treating small and localized tumors and is a promising alternative for patients who are not eligible for traditional surgery. The rising adoption of this treatment modality due to its minimally invasive nature and high precision approach is significantly contributing to the Middle East and Africa tumor ablation market growth.

In the Middle East and Africa, cancer is becoming one of the leading causes of disease burden, with patient numbers projected to

sharply rise in the coming decades . Recent data reveals that the number of new cancer cases in Saudi Arabia is estimated to reach 60,429 by 2040 , indicating the need for effective interventions to treat the growing patient pool. Since tumor ablation can be used in the treatment of various types of cancers, including liver, kidney, lung, and bone cancers, the high cancer incidence is expected to directly impact the Middle East and Africa tumor ablation market demand.

One of the major market trends is the increasing introduction of advanced ablation techniques in healthcare facilities in the region due to their higher efficacy and fewer side effects. In January 2023, Tawam Hospital, part of the Abu Dhabi Health Services Company (the United Arab Emirates' largest healthcare network) announced that they used a thyroid radiofrequency and microwave ablation procedure for the first time to treat a patient with a large compressive benign thyroid nodule. Further, they shared that the patient was successfully treated with this novel procedure and was discharged after an hour. The growing recognition of tumor ablation technique as a reasonable alternative to surgery is likely to improve patient outcomes and quality of life, thereby elevating the Middle East and Africa tumor ablation market value.

The market is also influenced by the increased government initiatives aimed at improving cancer care and treatment access. For instance, in August 2023, the Federal Ministry of Health, Federal Capital Territory Administration, the Clinton Health Access Initiative, Medicaid Cancer Foundation, and City Cancer Challenge Foundation (C/Can) signed a Memorandum of Understanding to tackle the cancer burden in Abuja (Nigeria) and improve cancer care across the region. The multi-stakeholder commitment is to facilitate the reduction of cancer incidence and mortality through sustainable cancer care solutions. Such collaborative efforts are poised to increase access to innovative cancer treatment options including tumor ablation therapy in the region, which is anticipated to boost the market share.

Middle East and Africa Tumor Ablation Market Segmentation??

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Technology

? Radiofrequency Ablation

? Microwave Ablation

? Cryoablation

? Irreversible Electroporation Ablation

?[Others

Market Breakup by Application
? Kidney Cancer
! Liver Cancer
! Lung Cancer
! Bone Metastasis
! Others

Market Breakup by Mode of Treatment
?
Surgical Ablation

Claparoscopic Ablation

Clapercutaneous Ablation

Clapercutaneous Ablation

Market Breakup by End User ?□Hospitals and Clinics ?□Specialty Centers ?□Others

Market Breakup by Country -∏Saudi Arabia

Scotts International, EU Vat number: PL 6772247784

- -∏United Arab Emirates
- -[Nigeria
- □ South Africa
- Others

Leading Players in the Middle East and Africa Tumor Ablation Market

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- -□Medtronic Plc
- Angiodynamics
- Mermaid Medical
- □ Health Tronics
- -□Galil Medical Inc.
- -□EDAP TMS S.A.
- -□Boston Scientific Corporation
- -∏SonaCare Medical
- Misonix, Inc.
- -□NeuWave Medical, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

-\|\What is the Middle East and Africa tumor ablation market forecast outlook for 2024-2032?

The Middle East and Africa tumor ablation market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 14.2% during the forecast period of 2024-2032 and is likely to reach a market value of USD 6.3 billion by 2032.

- What are the major factors aiding the Middle East and Africa tumor ablation market demand?

The rising incidence of cancer and advancements in tumor ablation techniques are fuelling the demand for the market.

- What are the major Middle East and Africa tumor ablation market trends?

One of the significant trends in the market is the rising introduction of advanced ablation techniques in healthcare facilities to treat cancer. In January 2023, Tawam Hospital in the United Arab Emirates announced that they performed a microwave ablation and thyroid radiofrequency procedure to treat a patient with large compressive benign thyroid nodule.

-\(\subseteq \) What is the market segmentation based on the technology?

Based on the technology, the market is segmented into radiofrequency (RF) ablation, microwave ablation, cryoablation, and irreversible electroporation, among others.

- \square What is the market breakup by mode of treatment?

By mode of treatment, the market is divided into surgical ablation, laparoscopic ablation, and percutaneous ablation, among others.

-□What are the major end users of the market?

End users of the market are hospitals, clinics and specialty centers, among others.

-□What are the applications of the market?

Major applications of the market include liver cancer, lung cancer, kidney cancer, and bone metastasis, among others.

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- What is the market segmentation by countries?

The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

- Who are the key players involved in the Middle East and Africa tumor ablation market?

The key players in the market are Medtronic Plc, AngioDynamics, Mermaid Medical, HealthTronics, Galil Medical Inc., EDAP TMS S.A., Boston Scientific Corporation, SonaCare Medical, Misonix, Inc., and NeuWave Medical, Inc.

Meta description

The Middle East and Africa tumor ablation market is poised for growth, driven by the expansion of the global market, which was valued at USD 1.9 billion in 2023 and is projected to grow at a CAGR of 14.2% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Tumor Ablation Market Overview
 - 3.1 Middle East and Africa Tumor Ablation Market Historical Value (2017-2023)
 - 3.2 Middle East and Africa Tumor Ablation Market Forecast Value (2024-2032)
- 4 Middle East and Africa Tumor Ablation Market Landscape*
 - 4.1 Middle East and Africa Tumor Ablation: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Middle East and Africa Tumor Ablation: Product Landscape
 - 4.2.1 Analysis by Technology
 - 4.2.2 Analysis by Mode of Treatment
 - 4.2.3 Analysis by Application
- 5 Middle East and Africa Tumor Ablation Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Analysis
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis

Scotts International, EU Vat number: PL 6772247784

- 6 Middle East and Africa Tumor Ablation Market Segmentation (2017-2032)
 - 6.1 Middle East and Africa Tumor Ablation Market (2017-2032) by Technology
 - 6.1.1 Market Overview
 - 6.1.2 Radiofrequency (RF) Ablation
 - 6.1.3 Microwave Ablation
 - 6.1.4 Cryoablation
 - 6.1.5 Irreversible Electroporation
 - 6.1.6 Others
 - 6.2 Middle East and Africa Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 6.2.1 Market Overview
 - 6.2.2 Surgical Ablation
 - 6.2.3 Laparoscopic Ablation
 - 6.2.4 Percutaneous Ablation
 - 6.2.5 Others
 - 6.3 Middle East and Africa Tumor Ablation Market (2017-2032) by Application
 - 6.3.1 Market Overview
 - 6.3.2 Liver Cancer
 - 6.3.3 Lung Cancer
 - 6.3.4 Kidney Cancer
 - 6.3.5 Bone Metastasis
 - 6.3.6 Others
 - 6.4 Middle East and Africa Tumor Ablation Market (2017-2032) by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospital and Clinics
 - 6.4.3 Specialty Centers
 - 6.4.4 Others
 - 6.5 Middle East and Africa Tumor Ablation Market (2017-2032) by Countries
 - 6.5.1 Market Overview
 - 6.5.2 Saudi Arabia
 - 6.5.3 United Arab Emirates
 - 6.5.4 Nigeria
 - 6.5.5 South Africa
 - 6.5.6 Others
- 7 Saudi Arabia Tumor Ablation Market (2017-2032)
 - 7.1 Saudi Arabia Tumor Ablation Market (2017-2032) by Technology
 - 7.1.1 Market Overview
 - 7.1.2 Radiofrequency (RF)Ablation
 - 7.1.3 Microwave Ablation
 - 7.1.4 Cryoablation
 - 7.1.5 Irreversible Electroporation
 - 7.1.6 Others
 - 7.2 Saudi Arabia Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 7.2.1 Market Overview
 - 7.2.2 Surgical Ablation
 - 7.2.3 Laparoscopic Ablation
 - 7.2.4 Percutaneous Ablation
 - 7.2.5 Others

- 7.3 Saudi Arabia Tumor Ablation Market (2017-2032) by Application
 - 7.3.1 Market Overview
 - 7.3.2 Liver Cancer
 - 7.3.3 Lung Cancer
 - 7.3.4 Kidney Cancer
 - 7.3.5 Bone Metastasis
 - 7.3.6 Others
- 7.4 Saudi Arabia Tumor Ablation Market (2017-2032) by End User
 - 7.4.1 Market Overview
 - 7.4.2 Hospital and Clinics
 - 7.4.3 Specialty Centers
 - 7.4.4 Others
- 8 United Arab Emirates Tumor Ablation Market (2017-2032)
 - 8.1 United Arab Emirates Tumor Ablation Market (2017-2032) by Technology
 - 8.1.1 Market Overview
 - 8.1.2 Radiofrequency (RF)Ablation
 - 8.1.3 Microwave Ablation
 - 8.1.4 Cryoablation
 - 8.1.5 Irreversible Electroporation
 - 8.1.6 Others
 - 8.2 United Arab Emirates Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 8.2.1 Market Overview
 - 8.2.2 Surgical Ablation
 - 8.2.3 Laparoscopic Ablation
 - 8.2.4 Percutaneous Ablation
 - 8.2.5 Others
 - 8.3 United Arab Emirates Tumor Ablation Market (2017-2032) by Application
 - 8.3.1 Market Overview
 - 8.3.2 Liver Cancer
 - 8.3.3 Lung Cancer
 - 8.3.4 Kidney Cancer
 - 8.3.5 Bone Metastasis
 - 8.3.6 Others
 - 8.4 United Arab Emirates Tumor Ablation Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Hospital and Clinics
 - 8.4.3 Specialty Centers
 - 8.4.4 Others
- 9 Nigeria Tumor Ablation Market (2017-2032)
 - 9.1 Nigeria Tumor Ablation Market (2017-2032) by Technology
 - 9.1.1 Market Overview
 - 9.1.2 Radiofrequency (RF)Ablation
 - 9.1.3 Microwave Ablation
 - 9.1.4 Cryoablation
 - 9.1.5 Irreversible Electroporation
 - 9.1.6 Others
 - 9.2 Nigeria Tumor Ablation Market (2017-2032) by Mode of Treatment

- 9.2.1 Market Overview
- 9.2.2 Surgical Ablation
- 9.2.3 Laparoscopic Ablation
- 9.2.4 Percutaneous Ablation
- 9.2.5 Others
- 9.3 Nigeria Tumor Ablation Market (2017-2032) by Application
 - 9.3.1 Market Overview
 - 9.3.2 Liver Cancer
 - 9.3.3 Lung Cancer
 - 9.3.4 Kidney Cancer
 - 9.3.5 Bone Metastasis
 - 9.3.6 Others
- 9.4 Nigeria Tumor Ablation Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Hospital and Clinics
 - 9.4.3 Specialty Centers
 - 9.4.4 Others
- 10 South Africa Tumor Ablation Market (2017-2032)
 - 10.1 South Africa Tumor Ablation Market (2017-2032) by Technology
 - 10.1.1 Market Overview
 - 10.1.2 Radiofrequency (RF)Ablation
 - 10.1.3 Microwave Ablation
 - 10.1.4 Cryoablation
 - 10.1.5 Irreversible Electroporation
 - 10.1.6 Others
 - 10.2 South Africa Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 10.2.1 Market Overview
 - 10.2.2 Surgical Ablation
 - 10.2.3 Laparoscopic Ablation
 - 10.2.4 Percutaneous Ablation
 - 10.2.5 Others
 - 10.3 South Africa Tumor Ablation Market (2017-2032) by Application
 - 10.3.1 Market Overview
 - 10.3.2 Liver Cancer
 - 10.3.3 Lung Cancer
 - 10.3.4 Kidney Cancer
 - 10.3.5 Bone Metastasis
 - 10.3.6 Others
 - 10.4 South Africa Tumor Ablation Market (2017-2032) by End User
 - 10.4.1 Market Overview
 - 10.4.2 Hospital and Clinics
 - 10.4.3 Specialty Centers
 - 10.4.4 Others
- 11 Regulatory Framework
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year

- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Funding and Investment Analysis
 - 13.1 Analysis by Funding Instances
 - 13.2 Analysis by Type of Funding
 - 13.3 Analysis by Funding Amount
 - 13.4 Analysis by Leading Players
 - 13.5 Analysis by Leading Investors
 - 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
 - 14.1 Analysis by Partnership Instances
 - 14.2 Analysis by Type of Partnership
 - 14.3 Analysis by Leading Players
 - 14.4 Analysis by Geography
- 15 Supplier Landscape
 - 15.1 Market Share by Top 5 Companies
 - 15.2 Medtronic Plc
 - 15.2.1 Financial Analysis
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Angiodynamics
 - 15.3.1 Financial Analysis
 - 15.3.2 Product Portfolio
 - 15.3.3 Demographic Reach and Achievements
 - 15.3.4 Mergers and Acquisitions
 - 15.3.5 Certifications
 - 15.4 Mermaid Medical
 - 15.4.1 Financial Analysis
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
 - 15.5 HealthTronics
 - 15.5.1 Financial Analysis
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
 - 15.6 Galil Medical Inc.
 - 15.6.1 Financial Analysis
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements

- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 EDAP TMS S.A.
 - 15.7.1 Financial Analysis
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 15.8 Boston Scientific Corporation
 - 15.8.1 Financial Analysis
 - 15.8.2 Product Portfolio
 - 15.8.3 Demographic Reach and Achievements
 - 15.8.4 Mergers and Acquisitions
 - 15.8.5 Certifications
- 15.9 SonaCare Medical
 - 15.9.1 Financial Analysis
 - 15.9.2 Product Portfolio
 - 15.9.3 Demographic Reach and Achievements
 - 15.9.4 Mergers and Acquisitions
 - 15.9.5 Certifications
- 15.10 Misonix. Inc.
 - 15.10.1 Financial Analysis
 - 15.10.2 Product Portfolio
 - 15.10.3 Demographic Reach and Achievements
 - 15.10.4 Mergers and Acquisitions
 - 15.10.5 Certifications
- 15.11 Neuwave Medical, Inc.
 - 15.11.1 Financial Analysis
 - 15.11.2 Product Portfolio
 - 15.11.3 Demographic Reach and Achievements
 - 15.11.4 Mergers and Acquisitions
 - 15.11.5 Certifications
- 16 Middle East and Africa Tumor Ablation Market Distribution Model (Additional Insight)
 - 16.1 Overview
 - 16.2 Potential Distributors
 - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
 - 18.1 Very Small Companies
 - 18.2 Small Companies
 - 18.3 Mid-Sized Companies
 - 18.4 Large Companies
 - 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
 - 19.1 Government Funded
 - 19.2 Private Insurance
 - 19.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.					
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total narket. The EMR team strives to make this section as comprehensive as possible.					
market. The LMK team strives to make this section as comprehensive as possible.					
Scotts International. EU Vat number: PL 6772247784 tel. 0048 603 394 346 e-mail: support@scotts-international.com					

www.scotts-international.com



☐ - Print this form

To place an Order with Scotts International:

Middle East and Africa Tumor Ablation Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

☐ - Complete the re	elevant blank fields and sign			
Send as a scann	ned email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$3999.00
Five User License Corporate License				\$5299.00
				\$6299.00
			VAT	
			Total	
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*	EU Vat / Tax ID / NIP number*			
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-04	
		Signature		

Scotts International. EU Vat number: PL 6772247784